New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021
Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy, compared to placebo plus paclitaxel (as per AIPAC study)
Fully funded by EOC Pharma, trial will involve approx. 152 patients across 20 clinical trial sites in China
Follows encouraging data from Immutep’s ongoing AIPAC Phase IIb study announced end of March and today and presented at the San Antonio Breast Cancer Symposium
Global webinar: 11 December at 8.30 am Australian Easter Daylight Time, details below
Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.